Avacta Group plc

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Japan’s largest R&D hub for bioventures and pharma startups, Shonan Health Innovation Park (Shonan iPark), has been in active talks with Korean bioventures and government groups over the formation of

UK-based biotech Avacta Group plc plans to action its proprietary Affimer and pre|CISION platforms in a wide range of disease areas – creating products that are easier to manufacture than traditiona